Year All2024202320222021202020192018201720162015201420132012201120102007 08.10.17 Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update - PD-1 Refractory Melanoma Cohort of ENCORE 601 Completes Enrollment - - First Patient Dosed in ENCORE 601 Colorectal Cancer Cohort - - Company to Host Conference Call Today at 4:30 p.m. ET - Read More 08.03.17 Syndax to Announce Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 10, 2017 WALTHAM, Mass. , Aug. 3, 2017 /PRNewswire/ -- Syndax (Nasdaq: SNDX) announced today that it will release its second quarter 2017 financial results on Thursday, August 10, 2017 , after the close of the U.S. financial markets. In connection with the earnings release, Syndax's management team will Read More 07.11.17 Preclinical Results Support Entinostat's Role in Targeting the Tumor Microenvironment to Enhance Immune Checkpoint Therapy -Results Published Online in Clinical Cancer Research Show Entinostat Inhibits Function of Myeloid Derived Suppressor Cells Resulting in Enhanced Antitumor Effect in Murine Models of Lung and Renal Cell Carcinoma- Read More 05.24.17 Syndax Prices Public Offering of Common Stock WALTHAM, Mass., May 24, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX) announced today the pricing of an underwritten public offering of 3,750,000 shares of its common stock at a price to the public of $13.25 per share. The gross proceeds to Syndax from this offering, before Read More 05.23.17 Syndax Announces Proposed Public Offering of Common Stock WALTHAM, Mass., May 23, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX) announced today that it plans to offer and sell, subject to market and other conditions, $50 million of its common stock in an underwritten public offering. There can be no assurance as to whether or when Read More 05.17.17 Syndax Announces Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma -31% objective response rate for first stage of the Phase 2 melanoma cohort of ENCORE 601- -Enrollment ongoing in Stage 2, along with biomarker analysis- - ENCORE 601 now enrolling expanded cohorts of melanoma and NSCLC patients progressed on or after anti-PD1 therapies, after meeting pre-specified Read More 05.16.17 Syndax Pharmaceuticals Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD-1 Therapies Pre-specified objective response criteria met for advancing to second stage Read More 05.15.17 Syndax Pharmaceuticals to Present at the 2017 UBS Global Healthcare Conference WALTHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced that Chief Executive Officer Briggs W. Read More 05.08.17 Syndax Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Clinical and Business Update Enrollment of second stage of melanoma cohort in Phase 2 ENCORE 601 trial proceeding ahead of schedule; expected to be completed in the third quarter Company to host conference call today at 4:30 p.m. ET WALTHAM, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. Read More 05.01.17 Syndax to Announce First Quarter 2017 Financial Results and Host Conference Call and Webcast on May 8, 2017 WALTHAM, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its first quarter 2017 financial results on Monday, May 8, 2017, after the close of the U.S. financial markets. In connection with the earnings release, Syndax's management team will host a Read More 04.27.17 Syndax Announces Expansion of Immuno-Oncology Collaboration Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Colorectal Cancer ENCORE 601 cohort to begin enrolling patients with microsatellite stable colorectal cancer Read More 04.20.17 Syndax Announces Entinostat Data to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting WALTHAM, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced a poster presentation highlighting Read More
08.10.17 Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update - PD-1 Refractory Melanoma Cohort of ENCORE 601 Completes Enrollment - - First Patient Dosed in ENCORE 601 Colorectal Cancer Cohort - - Company to Host Conference Call Today at 4:30 p.m. ET - Read More
08.03.17 Syndax to Announce Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 10, 2017 WALTHAM, Mass. , Aug. 3, 2017 /PRNewswire/ -- Syndax (Nasdaq: SNDX) announced today that it will release its second quarter 2017 financial results on Thursday, August 10, 2017 , after the close of the U.S. financial markets. In connection with the earnings release, Syndax's management team will Read More
07.11.17 Preclinical Results Support Entinostat's Role in Targeting the Tumor Microenvironment to Enhance Immune Checkpoint Therapy -Results Published Online in Clinical Cancer Research Show Entinostat Inhibits Function of Myeloid Derived Suppressor Cells Resulting in Enhanced Antitumor Effect in Murine Models of Lung and Renal Cell Carcinoma- Read More
05.24.17 Syndax Prices Public Offering of Common Stock WALTHAM, Mass., May 24, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX) announced today the pricing of an underwritten public offering of 3,750,000 shares of its common stock at a price to the public of $13.25 per share. The gross proceeds to Syndax from this offering, before Read More
05.23.17 Syndax Announces Proposed Public Offering of Common Stock WALTHAM, Mass., May 23, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX) announced today that it plans to offer and sell, subject to market and other conditions, $50 million of its common stock in an underwritten public offering. There can be no assurance as to whether or when Read More
05.17.17 Syndax Announces Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma -31% objective response rate for first stage of the Phase 2 melanoma cohort of ENCORE 601- -Enrollment ongoing in Stage 2, along with biomarker analysis- - ENCORE 601 now enrolling expanded cohorts of melanoma and NSCLC patients progressed on or after anti-PD1 therapies, after meeting pre-specified Read More
05.16.17 Syndax Pharmaceuticals Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD-1 Therapies Pre-specified objective response criteria met for advancing to second stage Read More
05.15.17 Syndax Pharmaceuticals to Present at the 2017 UBS Global Healthcare Conference WALTHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced that Chief Executive Officer Briggs W. Read More
05.08.17 Syndax Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Clinical and Business Update Enrollment of second stage of melanoma cohort in Phase 2 ENCORE 601 trial proceeding ahead of schedule; expected to be completed in the third quarter Company to host conference call today at 4:30 p.m. ET WALTHAM, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. Read More
05.01.17 Syndax to Announce First Quarter 2017 Financial Results and Host Conference Call and Webcast on May 8, 2017 WALTHAM, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its first quarter 2017 financial results on Monday, May 8, 2017, after the close of the U.S. financial markets. In connection with the earnings release, Syndax's management team will host a Read More
04.27.17 Syndax Announces Expansion of Immuno-Oncology Collaboration Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Colorectal Cancer ENCORE 601 cohort to begin enrolling patients with microsatellite stable colorectal cancer Read More
04.20.17 Syndax Announces Entinostat Data to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting WALTHAM, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced a poster presentation highlighting Read More